Bio Pharma Dive
JANUARY 4, 2024
Moonwalk Biosciences, the latest biotech cofounded by the gene editing scientist, joins other startups aiming to alter gene expression without changing DNA.
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 4, 2024
The next time you make yourself a berry smoothie, you might want to hold off on the banana. Sure, this fruit is full of potassium and makes a drink deliciously thick and creamy, but according to researchers from the University of California Davis (UCD), there’s something in bananas that might overpower the antioxidants in berries.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
JANUARY 4, 2024
The company plans to restructure and will start a new late-stage study testing whether its “off-the-shelf” therapy can boost cure rates when used early on.
Pharmaceutical Technology
JANUARY 4, 2024
Pfizer Canada has received Health Canada approval for gene therapy Beqvez (fidanacogene elaparvovec) for the treatment of haemophilia B.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
JANUARY 4, 2024
The agency could soon clear important new drugs from Eli Lilly and Merck, as well as the first treatment for a common liver disease.
Pharmaceutical Technology
JANUARY 4, 2024
Tonabersat is under clinical development by Inflammx Therapeutics and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
JANUARY 4, 2024
Tonabersat is under clinical development by Inflammx Therapeutics and currently in Phase II for Diabetic Macular Edema.
Bio Pharma Dive
JANUARY 4, 2024
The CRISPR specialist joins some of its genetic medicine peers in trimming staff, announcing an “organizational streamlining” to focus resources on prioritiy drug programs.
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 4, 2024
Dharwad District Chemists & Druggists Association (DDCDA) is devising strategies to differentiate their service with improved customer experience. These span attention to details like patient education to manage their medication, ensure fair business practices in pricing and dispensing medicines efficiently among others.
Bio Pharma Dive
JANUARY 4, 2024
The research deals with Omega Therapeutics and Cellarity are the first under a broad alliance Novo struck with Flagship last spring.
Pharmaceutical Technology
JANUARY 4, 2024
Tonabersat is under clinical development by Inflammx Therapeutics and currently in Phase II for Dry (Atrophic) Macular Degeneration.
Pharma Times
JANUARY 4, 2024
Metastatic cancer is estimated to be responsible for 90% of cancer deaths
Pharmaceutical Technology
JANUARY 4, 2024
BridGene has entered into a strategic partnership and licensing deal with Galapagos for the discovery of drug candidates for oncology targets.
Pharma Times
JANUARY 4, 2024
High amounts of disrupted sleep were found to affect memory and thinking performance
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Fierce Pharma
JANUARY 4, 2024
Use of Novo Nordisk and Eli Lilly’s popular diabetes and weight loss drugs come with warnings about a rare intestinal blockage condition called ileus, which can be life threatening. | Use of Novo Nordisk and Eli Lilly’s popular diabetes and weight loss drugs come with warnings about a rare intestinal blockage condition called ileus. Could cautions about more common side effects soon be added to the labels of popular treatments such as Novo’s Ozempic and Lilly’s Mounjaro?
pharmaphorum
JANUARY 4, 2024
Amplifying the patient voice is essential for the success of clinical trials. Learn why it is crucial for patient engagement, recruitment, and overall trial success, and how it can address challenges such as transportation and financial barriers.
Pharmaceutical Technology
JANUARY 4, 2024
Agios plans to file regulatory approval for mitapivat by the end of the year after it met primary endpoint in the Phase III trial.
Fierce Pharma
JANUARY 4, 2024
Despite competitive pressure from a buzzy CRISPR therapy, bluebird bio keeps striding forward with its sickle cell disease gene therapy Lyfgenia. | Despite competitive pressure from a buzzy CRISPR therapy, bluebird bio has signed a second outcomes-based reimbursement agreement for its sickle cell gene therapy Lyfgenia.
Pharmaceutical Technology
JANUARY 4, 2024
In a move to drive down customer costs, CVS will replace AbbVie’s blockbuster with more affordable biosimilars.
Fierce Pharma
JANUARY 4, 2024
Even after the heady highs of the COVID-19 era, the contract development and manufacturing organization (CDMO) realm remains one of biopharma's buzziest fields. | Even after the heady highs of the COVID era, the CDMO realm remains one of biopharma's buzziest fields. In 2024, CDMOs can advance their priorities on three fronts, a group of experts said during a recent Evaluate webinar on the state of the industry.
Pharmaceutical Technology
JANUARY 4, 2024
Daiichi Sankyo Europe (DSE) has amended its existing collaboration with Esperion Therapeutics valued at $125m.
Fierce Pharma
JANUARY 4, 2024
Already with a manufacturing site in Chiba, Japan, AGC Biologics is doubling down on its presence in the country with a new facility in Yokohama. | Already with a manufacturing site in Chiba, Japan, AGC Biologics is doubling down on its presence in the country with a new facility in Yokohama. The Seattle-based CDMO has unveiled its plan to construct a four-story complex, which will cover 20,000 square meters (215,000 square feet) and is expected to become operational in 2026.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
JANUARY 4, 2024
ENYO Pharma has secured €39m Series C funding to advance Vonafexor for the treatment of the kidney disease Alport syndrome.
Fierce Pharma
JANUARY 4, 2024
This year, CVS Health plans to employ the classic "out with the old, in with the new" mantra when it comes to AbbVie’s Humira. | The changes to major commercial formularies will take effect April 1 and favor Humira biosimilar options over the branded drug as part of CVS' efforts to ramp up U.S. biosimilar adoption.
XTalks
JANUARY 4, 2024
Pfizer has kickstarted the new year with its first-ever gene therapy approval, awarded by Health Canada to the company’s Beqvez (fidanacogene elaparvovec) for the treatment of hemophilia B. The adeno-associated viral (AAV) vector-based gene therapy received approval in Canada for the treatment of adults aged 18 years or older with moderately-severe to severe hemophilia B who are negative for neutralizing antibodies to variant AAV serotype Rh74, Pfizer Canada revealed in its announcement of the a
pharmaphorum
JANUARY 4, 2024
Scientists at Roche and Harvard University have discovered a new class of antibiotic that can kill carbapenem-resistant Acinetobacter baumannii (CRAB), a major public health threat
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Fierce Pharma
JANUARY 4, 2024
As bankers predict a rise in private equity exits this year, one of 2024’s M&A moves could come from the drug manufacturing realm. | Investment giant Bain Capital is weighing a potential sale of its Dutch antibiotics and active pharmaceutical ingredients (API) specialist Centrient Pharmaceuticals, which could be valued as high as €1 billion ($1.09 billion), Bloomberg reported Wednesday, citing people close to the talks.
pharmaphorum
JANUARY 4, 2024
Digital health company Click Therapeutics has won an FDA breakthrough device designation for CT-155, a digital therapeutic (DTx) for the negative symptoms of schizophrenia, like social withdrawal and apathy, that tend not to respond well to antipsychotic drugs.
Fierce Pharma
JANUARY 4, 2024
Merck has reportedly settled with insurance companies that contested the pharma giant’s $1.4 billion claim after it was victimized by a crippling cyberattack in 2017. | Merck has settled with insurance companies that contested the pharma giant’s $1.4 billion claim after it was victimized by a crippling cyberattack in 2017, Bloomberg Law reports. With the settlement—terms of which were not disclosed—the insurance companies avoided a ruling that would have provided precedent for other cases involv
pharmaphorum
JANUARY 4, 2024
CVS Health will remove AbbVie’s immunology blockbuster Humira from national lists of reimbursable products, and offer biosimilars of the drug instead
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
351 
Let's personalize your content